Contrast agents used to make magnetic resonance imaging, or MRI, scans easier to see should carry new, strong warnings, the U.S. Food and Drug Administration said on Wednesday.
The U.S. FDA indicated that it would start adding its strongest 'black box' warnings to gadolinium based contrast agents used in MRIs by May of next year.
Certain contrast agents used in magnetic resonance imaging, gadolinium-based products made by Bayer AG, GE and others, will now carry the U.S. Food and Drug Administration's strongest, "black box" warning.
Nephrogenic Systemic Fibrosis/ Nephrogenic Fibrosing Dermopathy (NSF/NFD), a painful conditions that has been linked to the use of gadolinium based contrast agents used in Magnetic Resonance Imaging (MRI), could be more prevalent than once thought.
New findings from researchers at Wake Forest University Baptist Medical Center and colleagues suggest why some people with kidney failure can develop a rare tightening and swelling of the skin and other organs, including the lungs and heart.
Kidney disease patients with a newly identified disease called nephrogenic systemic fibrosis (NSF) are at increased risk of death, U.S. researchers report.
